Actively Recruiting
Study on Functional Cure Approaches for Hepatitis B in Patients with HIV and Hepatitis B Coinfection Using ART With or Without Interferon Treatment
Led by Guangzhou 8th People's Hospital · Updated on 2023-08-14
60
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the potential to achieve a functional cure for hepatitis B in patients co-infected with HIV and hepatitis B virus HBV. This clinical observational cohort study focuses on patients who fit specific criteria and compares the effects of antiretroviral therapy ART alone against ART combined with interferon therapy. The study aims to observe rates of hepatitis B surface antigen seroclearance and seroconversion to evaluate the impact of these treatment strategies. Participants are divided into two groups based on their real-world treatment one group receives ART combined with pegylated interferon alfa-2b injections administered as 180 micrograms subcutaneously once a week, with follow-ups at baseline and weeks 4, 8, 12, 24, 36, 48, 60, and 72. The other group continues ART alone without interferon, with follow-ups at baseline and weeks 12, 24, 36, 48, 60, and 72. Each group includes 30 patients. During the study, participants undergo regular monitoring including blood tests to measure hepatitis B surface antigen levels, seroclearance, and seroconversion rates. Follow-up visits assess these outcomes at specified weeks up to week 72. The primary outcome is hepatitis B surface antigen seroclearance measured at 48 weeks. This approach helps researchers understand the functional cure potential and treatment responses in this patient population.
CONDITIONS
Brief Title
Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients
Research Team
L
Linghua Li, PhD
Y
Yaozu He, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here